Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity

  • Report Code : 1010939
  • Pages : 211
  • Published On : Nov 2023
  • Industry : Healthcare and Pharmaceuticals
  • Format :

Choose License Type

Single User License: US$ 3,200
Multi User License: US$ 4,500
Corporate User License: US$ 5,800
Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 111 tables and 87 figures, this 211-page report "Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.

Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines

Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases

By Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes

By Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases

Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
For each region and country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of all regional markets by country and the breakdown of each national market by Vaccine Type, Disease, and Administration over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 10
1.1 Industry Definition and Research Scope 10
1.1.1 Industry Definition 10
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of Market Research Methodology 14
1.2.2 Market Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 Market Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 Market Overview and Dynamics 22
2.1 Market Size and Forecast 22
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Market 27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
2.2 Major Growth Drivers 33
2.3 Market Restraints and Challenges 39
2.4 Emerging Opportunities and Market Trends 42
2.5 Porter's Fiver Forces Analysis 46
3 Segmentation of Global Market by Vaccine Type 50
3.1 Market Overview by Vaccine Type 50
3.2 Live/Attenuated Vaccines 52
3.3 Inactivated Vaccines 53
3.4 Subunit Vaccines 54
3.5 Toxoid Vaccines 55
3.6 Conjugate Vaccines 56
3.7 mRNA Vaccines 57
3.8 Recombinant Vector Vaccines 58
3.9 Other Vaccines 59
4 Segmentation of Global Market by Disease 60
4.1 Market Overview by Disease 60
4.2 Pneumococcal Disease 62
4.3 Poliovirus 63
4.4 Hepatitis 64
4.5 Influenza 65
4.6 Measles, Mumps, and Rubella (MMR) 66
4.7 Varicella 67
4.8 Human Papilloma Virus 68
4.9 COVID-19 69
4.10 Other Diseases 70
5 Segmentation of Global Market by Administration 71
5.1 Market Overview by Administration 71
5.2 Intramuscular Route 73
5.3 Subcutaneous Route 74
5.4 Oral Route 75
5.5 Intravenous Injection 76
5.6 Other Administration Routes 77
6 Segmentation of Global Market by Patient 78
6.1 Market Overview by Patient 78
6.2 Pediatric Vaccines 80
6.3 Adult Vaccines 82
7 Segmentation of Global Market by Region 84
7.1 Geographic Market Overview 2022-2032 84
7.2 North America Market 2022-2032 by Country 88
7.2.1 Overview of North America Market 88
7.2.2 U.S. 92
7.2.3 Canada 96
7.2.4 Mexico 99
7.3 European Market 2022-2032 by Country 102
7.3.1 Overview of European Market 102
7.3.2 Germany 106
7.3.3 U.K. 109
7.3.4 France 112
7.3.5 Spain 115
7.3.6 Italy 118
7.3.7 Russia 121
7.3.8 Rest of European Market 124
7.4 Asia-Pacific Market 2022-2032 by Country 126
7.4.1 Overview of Asia-Pacific Market 126
7.4.2 Japan 130
7.4.3 China 134
7.4.4 Australia 137
7.4.5 India 140
7.4.6 South Korea 143
7.4.7 Rest of APAC Region 146
7.5 South America Market 2022-2032 by Country 148
7.5.1 Argentina 151
7.5.2 Brazil 154
7.5.3 Chile 157
7.5.4 Rest of South America Market 160
7.6 MEA Market 2022-2032 by Country 161
7.6.1 UAE 164
7.6.2 Saudi Arabia 167
7.6.3 South Africa 170
7.6.4 Other National Markets 173
8 Competitive Landscape 174
8.1 Overview of Key Vendors 174
8.2 New Product Launch, Partnership, Investment, and M&A 177
8.3 Company Profiles 178
AstraZeneca plc 178
Bavarian Nordic A/S 180
China National Biotec Group Company Ltd. 183
CSL Ltd. 185
Daiichi Sankyo Co. Ltd 187
Emergent BioSolutions Inc. 189
GlaxoSmithKline plc 191
Johnson & Johnson 195
Merck & Co. 197
Moderna Inc. 199
Novavax, Inc. 200
Pfizer Inc. 202
Sanofi SA 206
Takeda Pharmaceutical Co. Ltd. 209
RELATED REPORTS 211

Data Center Preventive Maintenance Services Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)...

The Data Center Preventive Maintenance Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive la...

Vaccines Isothermal Boxes Market Size And Share Analysis - Growth Trends And Forecasts (2024-2031)...

The Vaccines Isothermal Boxes Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufactu...

Global Aircraft Preventive Maintenance Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Aircraft Preventive Maintenance Market: The report discusses everything a marketer requires before investing in the global Aircraft Preventive Maintenance Market during the forecast period 202...

Global Leadership Preventive Health Management Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Leadership Preventive Health Management Market: The report discusses everything a marketer requires before investing in the global Leadership Preventive Health Management Market during the for...

Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for p...

Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines s...

North America Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity...

North America preventive vaccines market is projected to grow by 6.3% annually in the forecast period and reach $46.90 billion by 2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for pre...

Global Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Region: Trend Forecast and Growth Opportunity...

Global preventive vaccines market will reach $120.07 billion by 2032, growing by 6.4% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as ...

Global Preventive Healthcare Planning Solutions Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Preventive Healthcare Planning Solutions Market: The report discusses everything a marketer requires before investing in the global Preventive Healthcare Planning Solutions Market during the f...

Global Preventive Healthcare Solutions Market Size, Key Players, Research Insights, Emerging Opportunities, COVID-19 Impact and Emerging Trends By 2030...

Overview of the Global Preventive Healthcare Solutions Market: The report discusses everything a marketer requires before investing in the global Preventive Healthcare Solutions Market during the forecast period 202...